Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab combination master protocol in previously untreated advanced or metastatic non-small cell lung cancer
2022-502738-18-00Phase 2Authorised
- Sponsor
- BeOne Medicines
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 15
01
Overview
Phase 2, open-label trial of tislelizumab, alcestobart, gimistotug and BGB-15025 in non-small cell lung cancer (NSCLC) (4 arms), sponsored by BeOne Medicines. Primary endpoint: Confirmed overall response rate. Planned start Sep 2023; status: authorised.
02
Drugs
tislelizumabalcestobartgimistotugBGB-15025
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-502738-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502738-18-00.